Introduction General Biological and Clinical Features of Schwannomas
Schwannomas (also called neuromas or neurilemmomas) are benign and usually encapsulated tumors originating from myelin-forming Schwann cells. 1 In general, schwannomas present as solitary sporadic lesions and consist of two components: a highly ordered cellular component composed of compact spindle or oval cells arranged in interlacing fascicles (Antoni A area) and a loose myxoid and less cellular component (Antoni B area).
2 Schwann cells in the Antoni B area have abundant lysosomes and myelin fibers with fragmented basal lamina, indicating that they may be degenerated from Antoni A areas.
3 Vestibular (acoustic) schwannomas originate from the eighth cranial nerve and localize either in the internal auditory canal or in the cerebellopontine angle.
3 Vestibular schwannomas are the fourth most common intracranial tumors 4 and exert slow but progressive growth. 3 Although they are benign, they can cause substantial morbidity including sensorineural hearing loss, vestibular dysfunction, and paralysis of facial nerves. 4 Larger tumors can lead to further paralysis of other cranial nerves and compression of the brainstem.
4
Vestibular schwannomas are managed clinically with three strategies: microsurgery, stereotactic radiation therapy, or serial radiologic monitoring.
5 A major problem is the differential growth pattern of these tumors, whose causes
are not yet clearly defined. 3 One of the problems is the large variation of tumor growth that complicates designing treatment strategies.
3 Surgical resection may involve full or partial tumor removal and carries risks such as sensorineural deafness, impairment of vestibular function, paralysis of facial nerves, leakage of cerebrospinal fluid, and meningitis.
Incomplete resection of vestibular schwannomas to preserve cranial nerve function necessitates deciphering novel pathologic mechanisms of aggressive schwannoma growth and developing new pharmacologic treatment strategies. We review the immunologic features of schwannomas that may improve treatment strategies. Schwannomas contain foamy macrophages and a wellformed capsule with lymphoid aggregates that help distinguish them from malignant peripheral nerve sheath tumors.
6 As outlined later in detail, prominent expression of proinflammatory mediators occurs in schwannomas that may contribute to tumor growth. We propose that one of the cardinal reasons for this feature is the loss of NF2/merlin protein. The percentage of cyst formation in vestibular schwannomas is 10%.
2 Cystic vestibular schwannomas behave more aggressively than their solid counterparts, with preoperative facial palsy, a short clinical history, unpredictable expansion of the cystic component, or hemorrhage. 13 Observation alone is not appropriate for these tumors, and rapid deterioration caused by cystic expansion or hemorrhage after radiosurgery does not support radiation therapy. 13 Abundant lymphocytes, foamy macrophages, and hemosiderin-laden macrophages exist in cystic schwannomas. 13 Intratumoral hemorrhage introduces robust inflammatory cell infiltration, specifically macrophages, and induces the release of proteinases including matrix metalloproteinase-2 that disrupts the tumor-nerve barrier and enhances adhesion to peritumoral tissues. 13 Fluid in these tumors is caused either by hemorrhage from hypervascular sites or by a collection of liquefied necrotic material.
13

Macrophages in Schwannomas and Their Correlation with Tumor Behavior
Tumor-associated macrophages can be roughly classified into two types. 14 These antigens may also mediate cell-to-cell contacts between neural cells. Among neural tumors, CD56 was highly present in 3 of 3 benign and 8 of 13 malignant schwannomas, whereas CD57 existed only moderately in one benign (of 3) and one malignant schwannoma (of 13). 14 These studies indicate that cell-to-cell contacts decrease during dedifferentiation of Schwann cells into schwannomas and/or attenuation of their immune surveillance by NK cells. However, these few studied samples hinder a definite conclusion.
NF-κB as a Major Transcription Factor of Proinflammatory Cytokines and Chemokines: Role of NF2/Merlin in Suppression of NF-κB
NF-κB is a transcription factor involved in cell growth, suppression of apoptosis, and the response to and induction of inflammatory stimuli. 9 Inflammatory cytokines induce activation of NF-κB, 9 and vice versa NF-κB activates transcription of inflammatory mediators 10 leading to positive inflammatory feedback. NF-κB complexes are formed by homo-or heterodimerization of a family of proteins that includes p50, p52, p65 (RelA), c-Rel, and RelB. NF-κB exists as an inactive complex in the cytoplasm via its binding with inhibitory proteins belonging to the IκB family. 9 Following NF-κB activating stimuli, such as tumor necrosis factor (TNF)α, IL-1, and various cellular stress signals, IκB is phosphorylated, ubiquitinated, and thereafter degraded by the 26S proteasome. induces degradation of IκB and subsequent nuclear translocation of NF-κB, where it induces expression of specific genes.
9
NIK and IKKα overexpression without NF2/merlin could induce NF-κB-dependent transcription that can be suppressed by NF2/merlin. 9 Additionally, NF2/merlin blocks p65, NIK, and IKKα in their transcriptional activation of NF-κB. 9 NF2/merlin also inhibits basal NF-κB activity in NIH3T3 and C6 cells and TNFα-induced transactivation of NF-κB. 9 NF-κB is responsible for constitutive expression of IL-1α, IL-6, IL-8/CXCL8, and granulocyte macrophage colony-stimulating factor in head and neck cancers.
10
NF-κB mediates basal transcription of TNFα, IL-1β, and platelet activating factor induction of cyclo-oxygenase-2 (COX-2).
10 NF-κB provides IL-1β, VEGF, lipopolysaccharide, 
Chemokine Expression in Schwannomas: MCP-1/CCL2, MIP-1α/CCL3, CXCL16 and Its Receptor CXCR6
Chemokines are a subgroup of cytokines with similar amino acid sequences that regulate chemotaxis of immunocytes and are classified into families of C-C and C-X-C.
2 The C-X-C chemokines induce neutrophil chemotaxis, whereas the C-C family, including macrophage inflammatory protein-1 (MIP-1α/CCL3), generally regulates monocytes/macrophage chemotaxis. 1 CXCL16 and CXCR6 mainly localize on S-100-positive schwannoma cells, and CXCL16 augments proliferation and migration of schwannoma cells. Salicylates including acetylsalicylic acid (universally known as aspirin) are strong suppressors of NF-κB, and they are proposed to be used as chemotherapy sensitizing agents in cancer treatment. 18 The major anti-inflammatory mechanism of salicylates is based on inhibition of COX enzymes and subsequently the production of prostaglandins (PTGs).
4
In 2014, by monitoring 347 vestibular schwannoma patients with serial magnetic resonance imaging, researchers found that aspirin slows schwannoma growth in patients. They demonstrated a prominent inverse association between aspirin consumption and growth of vestibular schwannomas that was not confounded by age or sex.
19 Furthermore, a bioinformatics-based network investigation determined NF-κB was a key factor in schwannoma tumorigenesis.
19
A year later the same group studied the effects of salicylates on schwannoma growth in vitro. 4 The efficacy of three different salicylates, aspirin, sodium salicylate, and 5-aminosalicylic acid, was tested against vestibular schwannomas because they are currently used clinically. 4 All salicylates were effective in decreasing proliferation and the vitality of vestibular schwannoma cells in vitro, accompanied by reduced secreted PTG levels. 
20
It should be noted that a considerable link exists between DCAF1 activity and inflammation-dependent carcinogenesis. 21 Chronic intestinal inflammation is closely associated with the development of colon cancer, and STAT3 plays a major role in linking chronic inflammation to the progression of colon cancer. 21 It was shown that DICER1 was significantly downregulated in response to inflammatory IL-6 or lipopolysaccharide stimulation, and the ubiquitin ligase complex of DCAF1 was responsible for the proteosomal degradation of DICER and its subsequent downregulation. 21 Noteworthy, the most prominent antitumor actions of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin are against colon cancer. 22-24 Furthermore, although mutations of merlin are rare in colon cancers ( 8%), 25 its protein expression is lowered in a higher ratio (20%) of sporadic colon cancers, and this decrease is correlated with tumor dedifferentiation.
endometrium cancers. [30] [31] [32] Overall, many interactions exist between molecular pathways of schwannoma and inflammation, and it is also plausible to perform experimental studies that combine NSAIDs with DCAF1 or MEK-ERK inhibitors to block proliferation of aggressively growing schwannoma cells.
Conclusion
Understanding the immune pathobiology of schwannomas may help develop novel and more efficient management strategies for subtypes that exert more aggressive growth and lesser responses to radiotherapy. Such approaches would encompass simple applications of aspirin derivatives or more sophisticated targeted drugs against specific cytokines and chemokines. For schwannomas that cannot be completely removed by neurosurgery or controlled by radiosurgery, pharmacologic interventions focusing on immune mechanisms seem suitable targets.
